Bevacizumab+TAXANE in 1L MBC
E2100: Pivotal Trial of Paclitaxel ± BV
•
Primary endpoint: PFS
•
Other endpoints: ORR, OS, QoL, safety
Previously
untreated LR/mBC
n=722
Stratification factors:
• DFI
• No. of metastatic sites
• Adjuvant chemotherapy
(yes vs no)
• ER status
Paclitaxel
a
Beva
10 mg/kg q2w
+ paclitaxel
a
Treat to disease
progression,
no crossover
permitted
Treat to disease
progression
Miller et al NEJM 2007 and Gray et al JCO 2009
Consistent PFS Benefit of BV/paclitaxel in all subgroups
